Fostamatinib (TAK-659 / M2951)
Immune Thrombocytopenia (ITP)
ApprovedCommercial
Key Facts
About Mochida Pharmaceutical
Founded in 1895, Mochida Pharmaceutical is a long-standing Japanese pharmaceutical company focused on the research, development, and commercialization of innovative medicines and healthcare products. The company operates across three core segments: Prescription Pharmaceuticals, Consumer Healthcare (OTC), and Diagnostics. Its strategy combines the lifecycle management of its established revenue-generating products with targeted R&D in areas such as oncology, immunology, and rare diseases to drive future growth.
View full company profileTherapeutic Areas
Other Immune Thrombocytopenia (ITP) Drugs
| Drug | Company | Phase |
|---|---|---|
| Fostamatinib (TAK-632/R788) | Nippon Shinyaku | Approved |